Octogenarians With Acute Myeloid Leukemia Have Poor Survival
Overall survival 1.5 months; survival improved for those receiving chemotherapy (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - May 21, 2019 Category: Cancer & Oncology Tags: Oncology, Pharmacy, Geriatrics, Journal, Source Type: news

Octogenarians With Acute Myeloid Leukemia Have Poor Survival
TUESDAY, May 21, 2019 -- Octogenarians with acute myeloid leukemia (AML) have a one-month mortality rate of 41 percent and overall survival (OS) of 1.5 months, according to a research letter published in the June issue of the American Journal of... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - May 21, 2019 Category: Pharmaceuticals Source Type: news

SERENA LIPSCOMB got her cancer all-clear aged eight... but the physical and mental toll never ends
SERENA LIPSCOMB, now 23, was living in Essex with her mother Melanie and father Ian when she was diagnosed with acute lymphoblastic leukaemia. (Source: the Mail online | Health)
Source: the Mail online | Health - May 18, 2019 Category: Consumer Health News Source Type: news

Researchers pinpoint why lymphoma patients may become resistant to specific therapy
(H. Lee Moffitt Cancer Center& Research Institute) Researchers from Moffitt Cancer Center and Dana-Farber Cancer Institute have discovered a mechanism of drug resistance to Venetoclax ® , also known as ABT-199, a BCL-2 targeting drug commonly used to treat chronic lymphocytic leukemia and acute myeloid leukemia. Their findings, published in the journal Cancer Cell, also suggest a possible co-treatment strategy to overcome this resistance. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - May 15, 2019 Category: Cancer & Oncology Source Type: news

FDA advisory panel votes against Daiichi Sankyo's blood cancer treatment
Independent experts on an advisory panel to the U.S. Food and Drug Administration on Tuesday voted against Daiichi Sankyo Co Ltd's treatment for adults with a type of acute myeloid leukemia. (Source: Reuters: Health)
Source: Reuters: Health - May 14, 2019 Category: Consumer Health News Tags: healthNews Source Type: news

Florida's medical police state abducts healthy three-year-old from parents for refusing unnecessary chemotherapy treatments
(Natural News) Another American family is facing a barrage of persecution from the corrupt medical establishment for refusing chemotherapy treatments for their three-year-old son, Noah – who doesn’t even have cancer, by the way. Young Noah had previously been diagnosed with acute lymphoblastic leukemia at Johns Hopkins All Children’s Hospital in Tampa, Florida, where his... (Source: NaturalNews.com)
Source: NaturalNews.com - May 6, 2019 Category: Consumer Health News Source Type: news

Enasidenib: A Promising Option for IDH2-Mutated Acute Myeloid Leukemia?
The authors explored the evidence supporting the safety and side effect profile of enasidenib, FDA-approved in August 2017 for relapsed/refractory AML. (Source: CancerNetwork)
Source: CancerNetwork - May 6, 2019 Category: Cancer & Oncology Authors: John Schieszer Source Type: news

New cancer therapy target found in mitochondria for potential treatment of blood cancers
(University of Texas M. D. Anderson Cancer Center) A study at The University of Texas MD Anderson Cancer Center identified a new therapeutic target in cancer cells and explains how new anti-cancer drugs called imipridones work by inducing cancer cell death in blood cancers, such as acute myeloid leukemia (AML) and mantle cell lymphoma. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - May 2, 2019 Category: Cancer & Oncology Source Type: news

Agios Announces FDA Approval of Tibsovo as Monotherapy for Newly Diagnosed Adult Patients with IDH1 Mutant Acute Myeloid Leukemia (AML) Not Eligible for Intensive Chemotherapy
CAMBRIDGE, Mass., May 02, 2019 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc., a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, today announced the U.S. Food and Drug Administration (FDA) approved a... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - May 2, 2019 Category: Drugs & Pharmacology Source Type: news

First major study of proteins in patients with acute lymphoblastic leukaemia
(Lund University) The most common form of childhood cancer is acute lymphoblastic leukaemia (ALL). Researchers at Lund University in Sweden, in cooperation with Karolinska Institutet, SciLifeLab and the University of Cambridge, have now carried out the most extensive analysis to date of ALL at the protein level, by studying the activity in over 8 000 genes and proteins. The results show aberrant folding in the DNA string, which in turn affects the genes' activity. The study was recently published in Nature Communications. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - April 25, 2019 Category: Cancer & Oncology Source Type: news

Two birds, one stone: Drug combo may prove effective against second type of leukemia
(Beth Israel Deaconess Medical Center) Researchers tested to see if arsenic trioxide (ATO) was effective in combination with all-trans retinoic acid (ATRA) in in both the mouse model of acute myeloid leukemia (AML) and in human AML cells in the lab, and determined that the combination proved 'powerfully and exquisitely effective' against a subset of AML. The combo could serve as the foothold researchers need to overcome resistance to therapy -- a common challenge in treating AML. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - April 25, 2019 Category: Cancer & Oncology Source Type: news

Model was in shape of his life when his sore throat turned out to be leukemia
William Yank, 21, from Indianapolis, Indiana, was diagnosed with acute lymphoblastic leukemia in June 2018. It was a shock to the college student, who was a model that worked out almost everyday. (Source: the Mail online | Health)
Source: the Mail online | Health - April 24, 2019 Category: Consumer Health News Source Type: news

Overlooked molecular machine in cell nucleus may hold key to treating aggressive leukemia
(Cincinnati Children's Hospital Medical Center) Many people fighting a very aggressive form of acute myeloid leukemia (AML) don't survive more than five years. These very sick patients are often unable to receive the only cure -- a bone marrow transplant. Now, an international team of scientists report in Nature Cell Biology on a long-overlooked part of a leukemic cell's internal machinery, where they may have found a key to treating the aggressive blood cancer. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - April 22, 2019 Category: Cancer & Oncology Source Type: news

The Leukemia Atlas: researchers unveil proteins that signal disease
(University of Texas at San Antonio) Only about one in four people diagnosed with acute myelogenous leukemia (AML) survive five years after the initial diagnosis. To improve that survival rate, researchers at The University of Texas at San Antonio (UTSA) and the University of Texas MD Anderson Cancer Center created an online atlas to identify and classify protein signatures present at AML diagnosis. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - April 17, 2019 Category: Cancer & Oncology Source Type: news

Scanning for cancer treatment
(Harvard University) 11,000 people are predicted to die from acute myeloid leukemia (AML) in 2019. Recently, drug developers designed a new treatment to target the cancer's mutated genes. But, these drugs don't always work. Now, in a new study, researchers investigate both sides of the drug-body relationship to better understand why certain AML treatments--and other cancer treatments--may not work as expected. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - April 15, 2019 Category: Cancer & Oncology Source Type: news

Presence of Leukemia Cutis Tied to Worse Survival in AML
THURSDAY, April 11, 2019 -- For patients with acute myeloid leukemia (AML), the presence of leukemia cutis (LC) is associated with decreased overall and leukemia-specific survival, according to a study published online April 10 in JAMA... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - April 11, 2019 Category: Pharmaceuticals Source Type: news

Venetoclax Plus LDAC May Benefit Patients with AML Ineligible for Intensive Chemotherapy
A new study evaluated combination venetoclax and low-dose cytarabine in previously untreated acute myeloid leukemia. (Source: CancerNetwork)
Source: CancerNetwork - April 8, 2019 Category: Cancer & Oncology Authors: John Schieszer Source Type: news

Phase III SIERRA Trial Finds Iomab-B Promising for Relapsed/Refractory AML
Researchers are evaluating  Iodine (131I) apamistamab plus HCT vs conventional care in older patients with active relapsed/refractory acute myeloid leukemia. (Source: CancerNetwork)
Source: CancerNetwork - April 8, 2019 Category: Cancer & Oncology Authors: John Schieszer Source Type: news

Daiichi Sankyo Provides Update on Ongoing FDA Review for Quizartinib for Treatment of Patients with Relapsed/Refractory FLT3-ITD AML
TOKYO and BASKING RIDGE, N.J., April 4, 2019 -- (Healthcare Sales & Marketing Network) -- Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) today announced that the U.S. Food and Drug Administration (FDA) has extended the review period for the N... Biopharmaceuticals, Oncology, FDA Daiichi Sankyo, quizartinib, acute myeloid leukemia, FLT3 inhibitor (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - April 4, 2019 Category: Pharmaceuticals Source Type: news

In the Loop: Gabe's bell to 'honor the fighting, remember the resting, and party on with the survivors'
Gabe Carranza walked into the lobby on the 16th floor of the Mayo Building. It was a walk he'd made more times than he could count over the past three years and 70 days. But this walk was different. It marked the end of Gabe's treatment for?acute lymphoblastic leukemia. The lobby was filled with family, [...] (Source: News from Mayo Clinic)
Source: News from Mayo Clinic - April 2, 2019 Category: Databases & Libraries Source Type: news

AACR: Longer Survival With Gilteritinib in FLT3mut & #43; AML
MONDAY, April 1, 2019 -- For patients with FMS-like tyrosine kinase 3 (FLT3) mutations who have relapsed or refractory acute myeloid leukemia (AML), gilteritinib results in longer overall survival and higher response rates than salvage chemotherapy... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - April 1, 2019 Category: Pharmaceuticals Source Type: news

New drug represents 'paradigm shift' in treatment of acute myeloid leukemia
A paradigm shift is underway in the treatment of acute myeloid leukemia: The newest of personalized medicines proved more effective and less toxic than standard chemotherapy for certain acute myeloid leukemia patients, new research indicates. (Source: CNN.com - Health)
Source: CNN.com - Health - April 1, 2019 Category: Consumer Health News Source Type: news

Gilteritinib improved survival for patients with acute myeloid leukemia
(American Association for Cancer Research) Treatment with the FLT3-targeted therapeutic gilteritinib (Xospata) improved survival for patients with relapsed or refractory acute myeloid leukemia (AML) harboring a FLT3 mutation compared with standard chemotherapy regimens, according to results from the ADMIRAL phase III clinical trial presented at the AACR Annual Meeting 2019, March 29-April 3. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - April 1, 2019 Category: Cancer & Oncology Source Type: news

Targeted drug for leukemia tested at Penn Medicine helps patients live longer
(University of Pennsylvania School of Medicine) An inhibitor drug that targets a specific mutation in relapsed or refractory acute myeloid leukemia (AML) helps patients live almost twice as long as those who receive chemotherapy. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - April 1, 2019 Category: Cancer & Oncology Source Type: news

Practice-Changing Results Seen in Phase III Relapsed/Refractory AML Trial
Results of the phase III ADMIRAL trial, which tested the FLT3 inhibitor gilteritinib in patients with relapsed/refractory acute myeloid leukemia, were presented at the AACR Annual Meeting. (Source: CancerNetwork)
Source: CancerNetwork - April 1, 2019 Category: Cancer & Oncology Authors: Dave Levitan Source Type: news

Five-year-old who won the nation’s heart in his battle against leukaemia has found a stem-cell donor
Oscar Saxelby-Lee, of St John's, Worcester, was diagnosed with the aggressive blood cancer acute lymphoblastic leukaemia on December 28 last year after his parents noticed bruising. (Source: the Mail online | Health)
Source: the Mail online | Health - March 29, 2019 Category: Consumer Health News Source Type: news

Genomic analysis offers roadmap for diagnosis and treatment of a high-risk leukemia
(St. Jude Children's Research Hospital) Acute erythroid leukemia (AEL) is a high-risk cancer with a dismal prognosis, uncertain genetic basis and controversy surrounding the diagnosis. That is changing, thanks to research led by St. Jude Children's Research Hospital that appears today in the journal Nature Genetics.The researchers completed the largest, most comprehensive genomic analysis yet of AEL and identified six age-related subgroups with distinct mutations and patterns of gene expression as well as treatment outcomes. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - March 29, 2019 Category: Cancer & Oncology Source Type: news

Moffitt CEO to be inducted into the 2019 Florida Inventors Hall of Fame
President and CEO of  Moffitt Cancer Center, Dr. Alan List, is being inducted into the 2019 Florida Inventors Hall of Fame for developing new therapeutic strategies for treating blood cancers. Internationally recognized for his contributions in the development of more effective treatment strategies for myelodysplasti c syndrome and acute myeloid leukemia, List's work led to the development of lenalidomide, which received approval from the U.S. Food and Drug Administration. The treatment transformed… (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - March 27, 2019 Category: Pharmaceuticals Authors: Kelsey Sunderland Source Type: news

HSCT Remains Standard in Childhood ALL, Despite CAR T-Cells HSCT Remains Standard in Childhood ALL, Despite CAR T-Cells
Clinicians should continue to rely on matched donor stem cell transplants to treat childhood acute lymphoblastic leukemia, while more data on novel CAR T-cell therapies is gathered, says German expert.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - March 26, 2019 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

New treatment of acute myeloid leukemia achieves remarkable results in a disease formerly with little hope
(Monash University) A new Australian drug trial has achieved a remarkable result, clearing the bone marrow of leukemia in almost 60 percent of patients. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - March 20, 2019 Category: International Medicine & Public Health Source Type: news

Favorable Outcomes Seen in Long Term for ALLR3 Trial
Findings for risk - stratified tx in B - cell precursor acute lymphoblastic leukemia, late bone marrow relapse (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - March 19, 2019 Category: Cancer & Oncology Tags: Oncology, Pathology, Pediatrics, Journal, Source Type: news

Favorable Outcomes Seen in Long Term for ALLR3 Trial
TUESDAY, March 19, 2019 -- For children with B-cell precursor acute lymphoblastic leukemia with late bone marrow relapse, risk stratification by minimal residual disease seems to be an effective strategy for treatment, according to a study recently... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - March 19, 2019 Category: Pharmaceuticals Source Type: news

Epigenetic protein could be new therapeutic target in acute myeloid leukemia
(Rockefeller University Press) British researchers have discovered that an epigenetic protein called EZH2 delays the development of acute myeloid leukemia (AML) but then switches sides once the disease is established to help maintain tumor growth. The study, which will be published March 19 in the Journal of Experimental Medicine, suggests that targeting EZH2 could therefore be an effective treatment for AML, an aggressive blood cancer expected to kill over 10,000 people in the US alone this year. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - March 19, 2019 Category: Cancer & Oncology Source Type: news

Only About Half of Elderly Newly Diagnosed With ALL Receive Tx
FRIDAY, March 8, 2019 -- Almost half of elderly patients newly diagnosed with acute lymphoblastic leukemia (ALL) do not receive treatment, according to a study recently published in Leukemia& Lymphoma. Christopher Kim, M.P.H., Ph.D., from Amgen... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - March 8, 2019 Category: Pharmaceuticals Source Type: news

Potential Link Between Industrial Pollutants and Acute Myeloid Leukemia Examined
A recent study evaluated whether living in an industrial city could be an important risk factor for developing AML. (Source: CancerNetwork)
Source: CancerNetwork - March 8, 2019 Category: Cancer & Oncology Authors: John Schieszer Source Type: news

Leukemia caused by collision with a wild pig? - Zimmermann M, Bendas G, Feldmann G.
HISTORY:  A 23 years old, previously healthy woman was admitted to our clinic with neutropenic fever to rule out acute leukemia. Upon admission the patient reported that a few days ago the carcass of a pig had fallen on her from above, so that she experi... (Source: SafetyLit)
Source: SafetyLit - March 7, 2019 Category: International Medicine & Public Health Tags: Non-Human Animals and Insects Source Type: news

Treosulfan Better Than Busulfan in Prep for HSCT Treosulfan Better Than Busulfan in Prep for HSCT
Older and sicker patients with acute myeloid leukemia undergoing stem cell transplant may fare better if they are given a treosulfan- rather than busulfan-based regimen, German scientists have shown.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - March 5, 2019 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Washington mom says she's cant vaccinate her five-year-old battling cancer and slams anti-vaxxers
Kai Bonneau, five, of Vancouver, Washington, has been battling acute lymphoblastic leukemia. He can't receive any vaccines until he's done with chemotherapy treatments. (Source: the Mail online | Health)
Source: the Mail online | Health - March 5, 2019 Category: Consumer Health News Source Type: news

Amgen Highlights Progress Of Innovative Early Oncology Pipeline With New Data At AACR 2019
First Preclinical Data to be Presented on AMG 510, a First-in-Class KRASG12C Inhibitor for Solid Tumors New Preclinical Data Evaluating AMG 757 to Highlight Half-Life Extended BiTE® Immunotherapy AMG 176 Preclinical Data Showcase Potential in Combination With Standard of Care Treatments for Acute Myeloid Leukemia THOUSAND OAKS, Calif., Feb. 28, 2019 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that new data from its early-stage oncology pipeline will be presented at the American Association for Cancer Research (AACR) Annual Meeting in Atlanta, March 29 – April 3, 2019. "At Amgen, we ar...
Source: Amgen News Release - February 28, 2019 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

An atlas of an aggressive leukemia
(Ludwig Institute for Cancer Research) A team of researchers led by Bradley Bernstein at the Ludwig Center at Harvard has used single-cell technologies and machine learning to create a detailed 'atlas of cell states' for acute myeloid leukemia (AML) that could help improve treatment of the aggressive cancer. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - February 28, 2019 Category: Cancer & Oncology Source Type: news

Atlas of acute myeloid leukemia cell types may lead to improved, targeted therapies
(Massachusetts General Hospital) A research team led by Massachusetts General Hospital investigators has assembled a detailed atlas of bone marrow cells from patients with acute myeloid leukemia, an aggressive blood cancer that usually leads to death within five years of diagnosis. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - February 28, 2019 Category: Cancer & Oncology Source Type: news

Genetic Variant Tied to Leukemia Risk in Hispanic Children
Novel susceptibility locus identified in the ERG gene for acute lymphoblastic leukemia (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - February 25, 2019 Category: Cancer & Oncology Tags: Oncology, Pathology, Pediatrics, Journal, Source Type: news

Genetic Variant Tied to Leukemia Risk in Hispanic Children
MONDAY, Feb. 25, 2019 -- Genetic variations have been identified in the ERG gene that are associated with an increased risk for acute lymphoblastic leukemia (ALL) in Hispanic children, according to a study recently published in Blood. Noting that... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - February 25, 2019 Category: Pharmaceuticals Source Type: news

Mother claims she took her daughter to the GP FIVE TIMES before she was diagnosed with leukaemia
Sharon Mcalister, 35, of Rutherglen, South Lanarkshire, alleges she took her daughter Kaiann to three separate GPs five times before the youngster was told she had acute lymphoblastic leukaemia. (Source: the Mail online | Health)
Source: the Mail online | Health - February 25, 2019 Category: Consumer Health News Source Type: news

After two deaths, FDA hits the brakes on leukemia treatment study
The FDA has placed a partial hold on a phase 1 study into the study of a treatment for acute myeloid leukemia (AML). (Source: PharmaManufacturing.com)
Source: PharmaManufacturing.com - February 20, 2019 Category: Pharmaceuticals Source Type: news

Mother, 35, discovers her cough that wouldn't shift is life-threatening LEUKAEMIA
Louise Moreton, from Melbourne, started feeling run-down after moving to Durham, England, with her husband and their son. She was quickly diagnosed with acute myeloid leukaemia. (Source: the Mail online | Health)
Source: the Mail online | Health - February 18, 2019 Category: Consumer Health News Source Type: news

Genetic variations in a fourth gene linked to elevated leukemia risk in Hispanic children
(St. Jude Children's Research Hospital) Progress reported on understanding why Hispanic children are more likely to develop acute lymphoblastic leukemia and to die of the disease. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - February 14, 2019 Category: Cancer & Oncology Source Type: news

Obesity Linked to Adverse Events in Children With Leukemia
WEDNESDAY, Feb. 13, 2019 -- For children with acute lymphoblastic leukemia (ALL), obesity is associated with an increased risk for adverse events during premaintenance chemotherapy, according to a study published in the February issue of Pediatric... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - February 13, 2019 Category: Pharmaceuticals Source Type: news

New therapy for aggressive blood cancer discovered
(University of Veterinary Medicine -- Vienna) Researchers at Vetmeduni Vienna and Ludwig Boltzmann Institute for Cancer Research have identified a new therapeutic strategy for Acute Myeloid Leukemia. They found that the activity of the mutated oncogenic protein C/EBPα is dependent on MLL1 histone methyltransferase complex. Laboratory tests showed that functional perturbation of MLL1 complex led to death of AML cells with C/EBPα mutations. Inhibitor treatment released the differentiation block of cancer cells and restored normal maturation of blood cells. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - February 13, 2019 Category: International Medicine & Public Health Source Type: news

Role of the ALK Inhibitor AZD3463 in Sorafenib-Resistant Acute Myeloid Leukemia
Investigators evaluated whether  AZD3463 can induce apoptosis in a dose-dependent manner in a subset of AML patients. (Source: CancerNetwork)
Source: CancerNetwork - February 8, 2019 Category: Cancer & Oncology Authors: John Schieszer Source Type: news